Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Baxter Healthcare Corporation | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Introduction : The most common technique used for ovarian cystectomy is the stripping technique. After stripping the cyst wall, the subsequent bleeding of the ovarian stromal wound is usually controlled by bipolar coagulation or/and by suturing. However, hemostasis achieved with bipolar coagulation could result in damage to the ovarian reserve. To avoid damage to healthy ovarian tissue, hemostasis using various topical hemostatic agents has been introduced to control post- cystectomy ovarian wound bleeding. Among these, FloSeal (Baxter Healthcare Corporation, Deer- field, IL, USA) is a hemostatic sealant composed of a gelatin-based matrix and thrombin solution.
Aim: The aim of the study is to evaluate the impact of topical hemostatic sealants and bipolar coagulation during laparoscopic ovarian benign cyst resection on ovarian reserve by comparing the rates of decrease in anti- Müllerian hormone (AMH).
Methods: A randomized prospective data collection was made on women aged 18-45 years who planned to have laparoscopic ovarian cystectomy at one of two institutions (n = 80), Montpellier University Hospital and Nimes University Hospital, France. Patients were randomly divided into two groups treated with either a topical hemostatic sealant (Floseal) or bipolar coagulation for hemostasis. Preoperative, 3-month and 6-month postoperative AMH levels were checked and the rates of decrease of AMH were compared.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BIPOLAR FORCEPS | Active Comparator | The bipolar forceps allow electrocoagulation and are part of the standard laparoscopy box, delivered by the sterilization service to the gynecology operating room. |
|
| FLOSEAL | Experimental | FLOSEAL® is a hemostatic agent based on gelatin of bovine origin added to thrombin of human origin. It is a recommended medical device in surgical procedures as an adjunct to hemostasis when control of bleeding, arterial jet seepage, ligation or any other conventional method proves impractical or ineffective. During this study, it will be used in 1st intention. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bipolar coagulation | Procedure | Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps. Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by bipolar coagulation. Then, the remnant tissue will be examined using irrigation and coagulated with minimal bipolar power (20-W current) on any sites that are bleeding. |
| Measure | Description | Time Frame |
|---|---|---|
| Serum anti-Mullerian hormone (AMH) level preoperative | A biological assessment with determination of the serum AMH level will be carried out for each patient during the preoperative consultation. | Between 2 and 17 days before cystectomy |
| Serum anti-Mullerian hormone (AMH) level at 3 months | A biological assessment with determination of the serum AMH level will be carried out for each patient, 3 months postoperatively. | 3 months after the cystectomy |
| Serum anti-Mullerian hormone (AMH) level at 6 months | A biological assessment with determination of the serum AMH level will be carried out for each patient, 6 months postoperatively. | 6 months after the cystectomy |
| Measure | Description | Time Frame |
|---|---|---|
| Time to achieve hemostasis | The time is measured in minutes from the end of the cystectomy to the end of hemostasis. | From the end of the cystectomy to the end of hemostasis (up to 1 hour) |
| Use of additional hemostatsis technique |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Martha DURAES, MD | Contact | +334 67 33 65 32 | m-duraes@chu-montpellier.fr | |
| Amélie DENOUEL, CRA | Contact | +334 67 33 55 72 | a-denouel@chu-montpellier.fr |
| Name | Affiliation | Role |
|---|---|---|
| Martha DURAES, MD | Montpellier University Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Montpellier | Montpellier | 34295 | France |
Not provided
| Label | URL |
|---|---|
| FLOSEAL user guide | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Coagulation by FLOSEAL haemostatic agent | Procedure | Cystectomy will be done via laparoendoscopic surgery After identifying the correct plane of cleavage, the stripping technique will be used. The cyst wall will be gently pulled down from the remaining ovary with two pairs of atraumatic forceps. Once the whole cyst wall will be separated from the ovary cortex, bleeding of the remaining ovarian stromal tissue will be controlled by either hemostatic sealants (FloSeal). Using a laparoscopic applicator, FloSeal will be applied to the surface of bleeding sites under direct vision and the ovarian cortex was gently pressed for 2 min with small gauze. |
|
Another technique can be used to achieve hemostasis: bipolar forceps, suture or second hemostasis agent. The other technique will be specified if it is used
| From the end of the cystectomy to the end of hemostasis, during surgery |
| Blood loss | Blood loss will be measured in ml throughout the surgery. | From the start of the surgery to the end of hemostasis |
| Intraoperative adverse effects | Adverse effects related to the coagulation procedure will be collected. | From the end of the cystectomy to the end of hemostasis |
| Revision surgery for bleeding at the operative site | In the event of bleeding at the operative site, revision surgery may be necessary. In this case the information will be collected. | From the end of the cystectomy to the end of hemostasis |
| CHU de Nîmes | Nîmes | 30029 | France |
|